Both galectin-1 and galectin-3 interact with oncogenic Ras, a proto-oncogene known to be mutated and constantly expressed in tumor cells rendering these two galectins to be favorable targets for therapy [81]. The gene discussed is LGALS3; the disease is neoplasm.